What is Apogee Therapeutics, Inc.'s D&A?

Apogee Therapeutics, Inc. (APGE) reported D&A of $408K in Q1 2026.

How has Apogee Therapeutics, Inc.'s D&A changed year-over-year?

Apogee Therapeutics, Inc.'s D&A increased by 97.1% year-over-year, from $207K to $408K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Apogee Therapeutics, Inc. APGE D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

Summit TherapeuticsSMMT

$44K+76.0%

Arrowhead ResearchARWR

$6.37M+4.7%

Immunovant, Inc.IMVT

——

Protagonist TherapeuticsPTGX

——

Segments

By segment

See full

Reportable Segment Aggregation Before Other Operating$408K+97.1%

Other financials

Income statement

See full

Operating income-$82.8M-31.2%

Net income-$74.1M-33.9%

EPS (diluted)-$1.06-11.6%

Balance sheet

See full

Cash & equivalents$451.8M+323%

Total debt$8.0M-31.9%

Total assets$1.3B+81.1%

Cash flow

See full

Operating cash flow-$55.6M-14.6%

CapEx$62.0K—

Free cash flow-$62.8M+7.3%

Valuation

See full

Market cap$6.81B+189%

Enterprise value$6.37B+181%

Returns & leverage

See full

Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s D&A?: Apogee Therapeutics, Inc. (APGE) reported D&A of $408K in Q1 2026.
How has Apogee Therapeutics, Inc.'s D&A changed year-over-year?: Apogee Therapeutics, Inc.'s D&A increased by 97.1% year-over-year, from $207K to $408K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.